Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines. Issue 69 (13th August 2018)

• Record Type: Journal Article
• Authors: Wu, Jun-Jun; Li, Wen-Hao; Chen, Pu-Guang; Zhang, Bo-Dou; Hu, Hong-Guo; Li, Qian-Qian; Zhao, Lang; Chen, Yong-Xiang; Zhao, Yu-Fen; Li, Yan-Mei
• Is Part Of: Chemical communications. Volume 54:Issue 69(2018)
• Page Start: 9655
• Page End: 9658
• Publication Date: 2018-08-13
• Subjects: Chemistry -- Periodicals; 540
• DOI: 10.1039/c8cc04860f
• Languages: English
• ISSNs: 1359-7345

Abstract

Abstract : STING agonist cyclic di-GMP was applied to glycopeptide cancer vaccines through physical mixing and built-in strategies for the first time. Abstract : Cyclic di-GMP (CDG) was applied to MUC1 glycopeptide-based cancer vaccines with physical mixing and built-in (at 2′-OH of CDG) strategies for activating the STING pathway. CDG in both strategies behaved as a potent immunostimulant and contributed to high titers of IgG antibodies and the expression of multiple cytokines.